Marksans Pharma Q4 Results 2026: Date, Revenue, PAT and Analyst Outlook
- May 5, 2026
- Posted by: Neeraj Pandey
- Category: News
Marksans Pharma (MARKSANS) Q4 results for FY26 are expected in May 2026. With Q3 FY26 revenue of Rs 602 Cr and PAT of Rs 92 Cr as the base, the street is watching closely for margin trajectory and management guidance on FY27 demand.
Get Free SEBI-Registered Research on Marksans Pharma — Click Here
Marksans Pharma Q4 FY26 Earnings Preview — What to Expect
The pharma sector is expected to deliver solid Q4 FY26 performance with stabilising US generic pricing, robust domestic formulation growth and a deepening complex generics pipeline supporting both revenue and margin expansion.
Marksans Pharma Q4 Results 2026 — Date and Key Estimates
| Parameter | Q3 FY26 Actual | Q4 FY26 Estimate | YoY Growth |
|---|---|---|---|
| Revenue (Rs Cr) | 602 | 648 | +8% |
| PAT (Rs Cr) | 92 | 105 | +14% |
| EBITDA Margin | — | 16.2% | Improvement expected |
| Results Date | — | May 2026 | — |
| Dividend History | Rs 1.00 per share | ||
| Dividend Expectation | Rs 2.00 final dividend expected | ||
Estimates based on analyst consensus as of April 2026. Actual results may vary. Verify before investing.
Track Marksans Pharma live price, FII/DII activity and fundamentals on Univest Screener
5 Reasons Marksans Pharma Q4 Results Could Beat Estimates
US Generics Business Recovery
Pricing erosion in US generics has moderated significantly. New ANDA approvals and first-to-file opportunities in high-value molecules are providing meaningful revenue upside for companies with deep US pipelines.
Domestic Formulations Growth
India’s domestic pharma market continues growing at 9 to 11 percent, driven by chronic therapy categories including cardiovascular, diabetes and respiratory, and expanding healthcare access in semi-urban India.
API Segment Expansion via China Plus One
China Plus One sourcing diversification by global pharma companies is creating strong and durable demand for Indian API manufacturers with robust quality regulatory track records.
Complex Generics and Biosimilars Pipeline
Companies investing in complex injectables, biosimilars and specialty drugs are building differentiated pipelines that command significantly higher pricing and margins than standard generics.
Emerging Market Revenue Diversification
Africa, Latin America and Southeast Asia revenues are growing robustly, providing geographical diversification beyond the US and India and reducing single-market concentration risk.
5 Key Risks to Watch in Marksans Pharma Q4 Results
USFDA Inspection and Import Alert Risk
USFDA facility inspections and import alerts remain a persistent overhang; any adverse observation or warning letter can materially disrupt US revenues for multiple quarters.
US Generics Price Erosion
Competition from Chinese and domestic US manufacturers can re-intensify pricing pressure in base generics molecules, eroding volumes and realisations unexpectedly.
Raw Material Cost Pressure
API and solvent prices, particularly China-sourced intermediates, can spike and compress gross margins sharply if supply disruptions occur.
DPCO Price Control Impact
Inclusion of additional drugs in the National List of Essential Medicines limits domestic pricing flexibility and can restrict revenue growth for affected portfolios.
Currency Risk on Export Revenues
Weakness in export destination currencies against INR reduces international revenue realisation and compresses overseas profitability.
Analyst Ratings and Target Price for Marksans Pharma
| Brokerage | Rating | Key Thesis |
|---|---|---|
| Bernstein | Outperform | US generics recovery and complex pipeline launches |
| CLSA | Buy | Domestic growth and API China Plus One opportunity |
| JM Financial | Buy | Margin expansion and emerging market revenue growth |
Analyst ratings are for informational purposes only and subject to change. Not investment advice.
Q4 Results 2026 Calendar — Key Dates to Track
| Company | Expected Results Date |
|---|---|
| Marksans Pharma | May 2026 |
| TCS | April 2026 |
| Infosys | April 2026 |
Stay updated on all Q4 FY26 earnings at Univest Blogs. For TCS results see TCS Q4 Results 2026 and for Infosys see Infosys Q4 Results 2026.
How to Invest in Marksans Pharma Based on Q4 Results
Before investing in Marksans Pharma based on Q4 results, consider the following approach: review the actual revenue and PAT versus analyst estimates, listen to the management earnings call for FY27 guidance, assess whether the EBITDA margin trajectory is improving or deteriorating, and check FII/DII activity patterns post-results. A beat on estimates with positive guidance is typically a bullish signal; a miss with downgraded guidance may indicate further correction risk.
Frequently Asked Questions — Marksans Pharma Q4 Results 2026
Q: When will Marksans Pharma announce Q4 FY26 results?
Marksans Pharma (MARKSANS) is expected to announce Q4 FY26 results in May 2026. The exact board meeting date will be communicated via BSE/NSE exchange filing. Track the date on Univest Screener.
Q: What is the revenue estimate for Marksans Pharma Q4 FY26?
Analyst consensus estimates Marksans Pharma Q4 FY26 revenue at approximately Rs 648 Cr, representing approximately 8% year-on-year growth. The actual number will depend on sector demand trends and execution in the quarter.
Q: What PAT is expected for Marksans Pharma in Q4 FY26?
Estimated PAT for Marksans Pharma Q4 FY26 is approximately Rs 105 Cr, up approximately 14% year-on-year. Margin expansion from operating leverage and input cost moderation are the primary drivers of profit growth expectations.
Q: Will Marksans Pharma declare a dividend in Q4 FY26?
Historical dividend pattern for Marksans Pharma: Rs 1.00 per share. For Q4 FY26, Rs 2.00 final dividend expected. Dividend declarations are subject to board approval at the time of results.
Q: What is the current share price and market cap of Marksans Pharma?
Marksans Pharma (MARKSANS) is currently trading at approximately Rs 278 with a market capitalisation of Rs 8,050 Cr. Track live price, volume and FII/DII data on Univest Screener.
Q: What are the key risks for Marksans Pharma in Q4 FY26?
Key risks include: USFDA Inspection and Import Alert Risk, US Generics Price Erosion, Raw Material Cost Pressure. Investors should monitor management commentary on these risks in the Q4 earnings call.
Q: Is Marksans Pharma a buy before Q4 results?
This article does not constitute investment advice. Whether to buy Marksans Pharma before Q4 results depends on your risk appetite, existing portfolio exposure and entry price relative to fair value. Consult a SEBI-registered financial advisor before making any investment decision.
Q: How can I track Marksans Pharma Q4 results live?
Track Marksans Pharma Q4 FY26 results live on the Univest Screener, which provides real-time price updates, financial data and analyst research. Download the Univest iOS App or Android App for mobile alerts.
Disclaimer: Investments in securities are subject to market risk. This content is for educational purposes only and does not constitute investment advice. Consult a SEBI-registered financial advisor before making any investment decisions. SEBI Registration: INH000012449.
Recent Article
Why Is Ahluwalia Contracts Share Price Falling Key Reasons 2026
Why Is Ahluwalia Contracts Share Price Falling Key Reasons 2026
Why Is Nuvoco Vistas Corporation Share Price Falling Key Reasons 2026
Why Is Capacite Infraprojects Share Price Falling Key Reasons 2026
